TipRanks
Nanobiotix (DE:5NRA)
FRANKFURT:5NRA
Germany Market
5NRA
Nanobiotix
RESEARCH TOOLSreports

Nanobiotix (5NRA) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

5NRA Analyst Ratings

Moderate Buy
3Ratings
Moderate Buy
2 Buy
1 Hold
0 Sell
Based on 3 analysts giving stock ratings to
Nanobiotix
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

5NRA Stock 12 Month Forecast

Average Price Target

€41.96
▲(16.57% Upside)
Based on 3 Wall Street analysts offering 12 month price targets for Nanobiotix in the last 3 months. The average price target is €41.96 with a high forecast of €57.14 and a low forecast of €26.79. The average price target represents a 16.57% change from the last price of €36.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"€14","25":"€25","36":"€36","47":"€47","58":"€58"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":57.14239808,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€57.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41.96394859,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€41.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.7854991,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€26.79</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,25,36,47,58],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26,28.39556908307692,30.791138166153846,33.18670724923077,35.58227633230769,37.977845415384614,40.37341449846154,42.768983581538464,45.164552664615385,47.56012174769231,49.95569083076923,52.35125991384616,54.74682899692308,{"y":57.14239808,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26,27.227996045384614,28.455992090769232,29.683988136153847,30.91198418153846,32.13998022692308,33.36797627230769,34.59597231769231,35.82396836307692,37.051964408461544,38.27996045384616,39.50795649923077,40.73595254461539,{"y":41.96394859,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26,26.060423007692307,26.120846015384615,26.181269023076922,26.24169203076923,26.302115038461537,26.362538046153844,26.422961053846155,26.483384061538462,26.54380706923077,26.604230076923077,26.664653084615384,26.72507609230769,{"y":26.7854991,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.9,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.7,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.8,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":17.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.4,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":33,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€57.14Average Price Target€41.96Lowest Price Target€26.79
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen Analyst forecast on DE:5NRA
Tara Bancroft
TD Cowen
TD Cowen
―
Buy
―
Reiterated
09/25/26
Analysts Offer Insights on Healthcare Companies: Celldex (NASDAQ: CLDX), Nanobiotix (NASDAQ: NBTX) and Senseonics Holdings (NASDAQ: SENS)
UBS Analyst forecast on DE:5NRA
David Dai
UBS
UBS
€26.79
Hold
-25.60%
Downside
Reiterated
09/25/26
Analyst Maintains Hold on Balanced Risk/Reward Ahead of Key 2027 Oncology Trial Readouts
Guggenheim Analyst forecast on DE:5NRA
Paul Jeng
Guggenheim
Guggenheim
€57.14
Buy
58.73%
Upside
Reiterated
09/25/26
Analysts Offer Insights on Healthcare Companies: Damora Therapeutics (NASDAQ: DMRA) and Nanobiotix (NASDAQ: NBTX)
Leerink Partners Analyst forecast on DE:5NRA
Jonathan Chang
Leerink Partners
Leerink Partners
€23.21→€33.04
Buy
-8.23%
Downside
Reiterated
04/01/26
Nanobiotix price target raised to $37 from $26 at LeerinkNanobiotix price target raised to $37 from $26 at Leerink
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen Analyst forecast on DE:5NRA
Tara Bancroft
TD Cowen
TD Cowen
―
Buy
―
Reiterated
09/25/26
Analysts Offer Insights on Healthcare Companies: Celldex (NASDAQ: CLDX), Nanobiotix (NASDAQ: NBTX) and Senseonics Holdings (NASDAQ: SENS)
UBS Analyst forecast on DE:5NRA
David Dai
UBS
UBS
€26.79
Hold
-25.60%
Downside
Reiterated
09/25/26
Analyst Maintains Hold on Balanced Risk/Reward Ahead of Key 2027 Oncology Trial Readouts
Guggenheim Analyst forecast on DE:5NRA
Paul Jeng
Guggenheim
Guggenheim
€57.14
Buy
58.73%
Upside
Reiterated
09/25/26
Analysts Offer Insights on Healthcare Companies: Damora Therapeutics (NASDAQ: DMRA) and Nanobiotix (NASDAQ: NBTX)
Leerink Partners Analyst forecast on DE:5NRA
Jonathan Chang
Leerink Partners
Leerink Partners
€23.21→€33.04
Buy
-8.23%
Downside
Reiterated
04/01/26
Nanobiotix price target raised to $37 from $26 at LeerinkNanobiotix price target raised to $37 from $26 at Leerink
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AMRXAmneal Pharmaceuticals
DNTHDianthus Therapeutics
REPLReplimune Group
VSTMVerastem
OVIDOvid Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Nanobiotix

3 Months
Tara BancroftTD Cowen
Success Rate
4/4 ratings generated profit
100%
Average Return
+32.65%
Copying Tara Bancroft's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +32.65% per trade.
1 Year
Tara BancroftTD Cowen
Success Rate
3/4 ratings generated profit
75%
Average Return
+17.50%
Copying Tara Bancroft's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +17.50% per trade.
2 Years
Jonathan ChangLeerink Partners
Success Rate
12/13 ratings generated profit
92%
Average Return
+492.72%
Copying Jonathan Chang's trades and holding each position for 2 Years would result in 92.31% of your transactions generating a profit, with an average return of +492.72% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

5NRA Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
0
0
0
2
2
Buy
5
1
0
1
1
Hold
2
2
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
3
1
4
4
In the current month, 5NRA has received 3 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 5NRA average Analyst price target in the past 3 months is 41.96.
Each month's total comprises the sum of three months' worth of ratings.

5NRA Financial Forecast

5NRA Earnings Forecast

Next quarter’s earnings estimate for 5NRA is €0.05 with a range of -€0.20 to €0.33. The previous quarter’s EPS was -€0.70. 5NRA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 5NRA has Performed in-line its overall industry.
Next quarter’s earnings estimate for 5NRA is €0.05 with a range of -€0.20 to €0.33. The previous quarter’s EPS was -€0.70. 5NRA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 5NRA has Performed in-line its overall industry.

5NRA Sales Forecast

Next quarter’s sales forecast for 5NRA is €23.74M with a range of €4.47M to €43.39M. The previous quarter’s sales results were €3.79M. 5NRA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 5NRA has Performed in-line its overall industry.
Next quarter’s sales forecast for 5NRA is €23.74M with a range of €4.47M to €43.39M. The previous quarter’s sales results were €3.79M. 5NRA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 5NRA has Performed in-line its overall industry.

5NRA Stock Forecast FAQ

What is DE:5NRA’s average 12-month price target, according to analysts?
Based on analyst ratings, Nanobiotix’s 12-month average price target is 41.96.
    What is DE:5NRA’s upside potential, based on the analysts’ average price target?
    Nanobiotix has 16.57% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Nanobiotix a Buy, Sell or Hold?
          Nanobiotix has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Nanobiotix’s share price target?
            The average share price target for Nanobiotix is 41.96. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €57.14 ,and the lowest forecast is €26.79. The average share price target represents 16.57% Increase from the current price of €36.
              What do analysts say about Nanobiotix?
              Nanobiotix’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.
                How can I buy shares of Nanobiotix?
                To buy shares of DE:5NRA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.